BPIM: Bronchiectasis Phenotype Identification Model — Methodological Disclosure, Protocol, and Statistical Analysis Plan

The Bronchiectasis Phenotype Identification Model (BPIM) is developed within the Assiut University prospective bronchiectasis translational research platform as a supervised baseline phenotype-translation framework for adults with non-cystic fibrosis bronchiectasis.

BPIM follows a two-step analytical architecture. First, latent clinical trajectory analysis (LCTA) identifies trajectory-derived bronchiectasis phenotype classes using prospectively collected longitudinal data. Second, BPIM translates the accepted LCTA-derived phenotype structure into a supervised baseline classifier using the locked K5 baseline disease-signature parameter set.

The BPIM framework is methodologically separated from the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework while sharing the same baseline disease-signature engine. BASE-S classifies current bronchiectasis severity, BASE-P predicts 12-month exacerbation risk, and BPIM predicts the accepted LCTA-derived phenotype class.

This restricted-access record provides methodological time-stamping, intellectual record establishment, and structural governance for the BPIM disclosure document, protocol, and deterministic statistical analysis plan before final phenotype derivation and validation. The record documents the conceptual architecture, K5 input engine, LCTA-to-BPIM translational pathway, trajectory-variable ledger, phenotype-labeling convention, supervised classifier structure, development-validation governance, and validation restrictions.

Public metadata associated with this record do not constitute permission for unrestricted use, reproduction, modification, redistribution, derivative implementation, software incorporation, or commercial use of the protected BPIM framework or associated materials.

© 2026 Faculty of Medicine, Assiut University, Assiut, Egypt. Licensed under CC BY-NC-ND 4.0.